Member Info for liquid1

Baron Oil says historical Shell data indicates potential of East Timor play
04 February 2020, 13:56Source - SMW
Baron Oil said historical data complied by Shell indicated the promise of the Chuditch discovery offshore East Timor.

The Chuditch-1 well had been drilled by Shell a few decades ago and encountered a 25 metre gas column.

Shell estimated a total gross estimate of mean gas in place of 2.32 trillion cubic feet, with gas recovery expected in the range of 55%-to-75%.

Baron said it planned to invest in the Chuditch production sharing contract project through its entitlement to a one-third shareholding in SundaGas TLS, equating to an indirect net 25% interest in the contract.

'The information from the Shell reports gives a clear indication of the substantial potential for hydrocarbons within the Chuditch production sharing contract and the reason that Baron has maintained its entitlement to invest into SundaGas TLS since 2016,' executive chairman Malcolm Butler said.

'Now that the Chuditch PSC has been confirmed and the guarantee bond posted, the work programme over the next three years is designed to further define the size of the Greater Chuditch accumulation and the potential of nearby untested prospects, through seismic reprocessing and drilling, in order to formulate plans for commercialisation.

'The figures computed by Shell clearly indicate the size of the potential prize.'

We are behind

NOVACYT
0.4440 EUR
+ 2.54%
FR0010397232 ALNOV

Gone blue!

Here 16%

Mm are a joke!

200 cases in 20 countries -
WHO has launched a call for funds of 675 million dollars (613 million euros) and announced that 500,000 masks, 350,000 pairs of gloves will be sent to 24 countries, as well as 250,000 tests in more than 70 laboratories worldwide .

https://www.boursorama.com/bourse/actualites/coronavirus-563-morts-en-chine-les-mesures-de-restrictions-s-etendent-dans-le-monde-243803014b03039ea380b62b032e077f

Is this the same??

https://www.genesig.com/assets/files/CORONAVIRUS_2019_nCoV_Flyer_2.pdf

The 2019-nCoV Real-Time RT-PCR Diagnostic Panel had been in use already, but only at Centers for Disease Control and Prevention (CDC) labs. It relies on respiratory secretions from nasal or oral swabs, with a so-called reverse transcriptase polymerase chain reaction indicating whether the sample comes from someone infected by the new coronavirus.

https://www.google.co.uk/amp/s/www.slashgear.com/coronavirus-test-gets-emergency-approval-by-us-fda-05608570/amp/

Having tests makes it possible to manage the spread:
- isolate the patients as soon as possible to avoid contagions,
- react quickly when symptoms close to the disease, -
identify the affected geographic areas as soon as possible to put in place the necessary measures ...

So YES a test is very useful while waiting for vaccines or remedies.

And in a second step, the test will be used to determine precisely who to treat rather than doing it blindly: better targeting of priorities.

In short, the test is necessary and complementary to the rest (vaccine ° + treatment), knowing that for the moment we have neither vaccine nor treatment.

So we do with what we have, hence the importance of tests like that of NOVACYT

The CDC submitted a request for emergency authorization to the FDA on Monday. Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, said at that time that the approval would significantly expand the US’s ability to test people suspected of having the virus. She said the CDC had already shipped the test to the International Reagent Resource, the central distributor for diagnostic tests, so it would be available as soon as approval came through.

https://www.theverge.com/2020/2/5/21124005/fda-emergency-approval-coronavirus-test-cdc-diagnostic-health-labs

VOLUME

13,324,934

VALORIZATION

26 MEUR

TRADED CAPITAL

22.94%

5 FEBRUARY 2020 NEWS
FDA approves emergency use of coronavirus diagnostic test

FDA Commissioner Stephen Hahn said: “Since this outbreak first emerged, we’ve been working closely with our partners across the US government and around the globe to expedite the development and availability of critical medical products to help end this outbreak as quickly as possible. This continues to be an evolving situation and the ability to distribute this diagnostic test to qualified labs is a critical step forward in protecting public health.”

Last month, Primerdesign, the molecular diagnostics division of Clinical diagnostics company Novacyt, launched a molecular research use only (RUO) test for coronavirus. However, it is capable of detecting only the 2019 strain of the virus.

https://www.medicaldevice-network.com/news/fda-coronavirus-test/

https://www.google.co.uk/amp/s/www.dailymail.co.uk/news/article-7966321/amp/Fears-spike-UK-coronavirus-cases-thousands-continue-flooding-UK-China.html

“Later this week” FDA approval......

The Centers for Disease Control and Prevention wants the U.S. Food and Drug Administration to quickly grant an emergency authorization to use its Wuhan coronavirus diagnostic test so it can distribute it to laboratories across the country later this week.

Must be NCYT, because CEO states:..........

Graham Mullis, CEO of the Paris-based company, told BioWorld. By validating it with the specific sequence of the genome found in the new strain of the virus, the test delivers high levels of assay performance, particularly specificity – an advantage over tests that may react to related species, he said.

The Novacyt test is designed to run on multiple molecular testing platforms, including Primerdesign’s Genesig q16 and 132 instrument, making it suitable for large and small laboratories. It is also stable at ambient temperatures, removing the need for cold chain shipping, which could reduce transportation costs and loss of product.

Novacyt is currently making the test available to laboratories as a research use-only assay throughout its sales channels, and has seen strong, early demand from more than 10 countries. As for broader availability, the company is still determining the best route forward.

“In the event a manufacturer pursued full regulatory approval for clinical use, it could take six months or more with regulators such as the FDA,” he said. “There is an emergency use process with most regulators, and this might reduce the time for a limited approval within weeks, depending upon the criteria the regulators require.

https://www.bioworld.com/articles/432812-novacyt-launches-test-for-new-coronavirus

No idea?

Hope it is

The Centers for Disease Control and Prevention wants the U.S. Food and Drug Administration to quickly grant an emergency authorization to use its Wuhan coronavirus diagnostic test so it can distribute it to laboratories across the country later this week.

https://www.politico.com/states/new-york/newsletters/politico-new-york-health-care/2020/02/04/cdc-urges-expedited-coronavirus-testing-for-localities-332350

https://pulsenews.co.kr/view.php?year=2020&no=108967

These guys are way behind based on NCYT tech!

Korean diagnostic kit developers are gearing up to fast track the detection of the new deadly coronavirus which is spreading at a breakneck speed in China and around the world, with some expecting to reach the commercial markets within this month.
Kogene Biotech recently developed a gene diagnostic agent for the virus and submitted documents to Korea Centers for Disease Control and Prevention (KCDC) for emergency use assessment and listing (EUAL).

The EUAL procedure was set up as an extraordinary process to allow the use of in-vitro diagnostic (IVD) products without formal approval during the epidemic. The new reagent was developed according to the detection method guidelines announced by the World Health Organization and KCDC. A company official said demand is rising from Japan and several countries in Europe and Southeast Asia where confirmed cases are reported, and actual orders and commitments are expected to be made after the upcoming Medlab Expo in Dubai this week.

According to Biotech Policy Research Center, the worldwide IVD market that includes diagnostic kits for virus detection is expected to grow to $127 billion in 2022 from $42.7 billion in 2013.

New York City medical labs can’t run their own diagnostic tests for the novel coronavirus (2019-nCoV), and Mayor Bill de Blasio is pushing the Centers for Disease Control to speed up the bureaucratic process so the city can start doing so.

Over the weekend, the first three suspected cases were reported in New York City. Hospitals here, however, still have to depend on the CDC to run a new diagnostic test. Samples need to be sent to Atlanta, and results can take from 36-48 hours.

“We asked for [the test] a week ago, we’re still asking for it, they better pull out all the stops because the faster they do that, the better off everyone will be,” de Blasio told reporters at a press conference on Sunday.

https://brooklyneagle.com/articles/2020/02/03/de-blasio-to-cdc-give-new-york-city-the-coronavirus-test/